LLY

1,103

-2.23%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

AZN

185.53

-0.15%↓

LLY

1,103

-2.23%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

AZN

185.53

-0.15%↓

LLY

1,103

-2.23%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

AZN

185.53

-0.15%↓

LLY

1,103

-2.23%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

AZN

185.53

-0.15%↓

LLY

1,103

-2.23%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

AZN

185.53

-0.15%↓

Home・Aktien・Johnson and Johnson

Johnson and Johnson

Geschlossen

BrancheGesundheitswesen

225.18 -2.6

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

224.96

Max

225.69

Schlüsselkennzahlen
By Trading Economics
Einkommen	119M 5.2B
Verkäufe	-502M 24B
KGV Branchendurchschnitt	27.186 50.102
EPS	2.7
Dividendenrendite	2.24
Gewinnspanne	21.756
Angestellte	138,200
EBITDA	182M 6.4B

Empfehlungen
By TipRanks
Empfehlungen	Buy
12-Monats-Prognose	+18.23% upside

Dividenden
By Dow Jones
Dividendenrendite Branchendurchschnitt	2.24% 2.33%
Nächstes Ergebnis	15. Juli 2026
Nächste Dividendenausschüttung	9. Juni 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-9.4B 564B
Vorheriger Eröffnungskurs	227.78
Vorheriger Schlusskurs	225.18

Nachrichtenstimmung

By Acuity

63%

37%

290 / 344 Ranking in Healthcare

Johnson and Johnson Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Peer-Vergleich

Kursveränderung

Johnson and Johnson Prognose

Kursziel

By TipRanks

18.23% Vorteil

12-Monats-Prognose

Durchschnitt 266.4 USD 18.23%

Hoch 285 USD

Tief 250 USD

Basierend auf 17 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Johnson and Johnson – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

17 ratings

Buy

Halten

Sell

Basierend auf 17 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Johnson and Johnson – Dist abgegeben haben.

Stimmung

By Acuity

290 / 344 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Johnson and Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke. this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. The company has a collaboration agreement with Stand Up To Cancer for research testing a combination of teclistamab and daratumumab to treat a rare disease AL amyloidosis. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.